LANTERN PHARMA
Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action. Lantern also rescues and revitalizes abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also ... from the inability to fully elucidate mechanisms of action that can suggest potent therapy combinations. Our approach, which leverages our RADR™ platform helps to provide rapid, meaningful insight to both of these central problems in oncology. Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.
LANTERN PHARMA
Industry:
Artificial Intelligence Biopharma Biotechnology Pharmaceutical Therapeutics
Founded:
2013-01-01
Address:
Dallas, Texas, United States
Country:
United States
Website Url:
http://www.lanternpharma.com
Total Employee:
11+
Status:
Active
Contact:
972-277-1136
Email Addresses:
[email protected]
Total Funding:
94.98 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Domain Not Resolving Euro IPv6 JsDelivr Cloudflare JS
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Checkmate Pharmaceuticals
Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
LabGenius
LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine.
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Employees Featured
Founder
Stock Details
Investors List
GPG Ventures
GPG Ventures investment in Series A - Lantern Pharma
Bios Partners
Bios Partners investment in Series A - Lantern Pharma
Green Park & Golf Ventures
Green Park & Golf Ventures investment in Funding Round - Lantern Pharma
Health Wildcatters
Health Wildcatters investment in Pre Seed Round - Lantern Pharma
Official Site Inspections
http://www.lanternpharma.com Semrush global rank: 3.46 M Semrush visits lastest month: 4.39 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Lantern Pharma"
About Us - Lantern Pharma Inc.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR ®, leverages over 100+ billion oncology …See details»
Company Information :: Lantern Pharma Inc. (LTRN)
Company Contact Lantern Pharma Inc. 1920 McKinney Avenue 7th Floor Dallas, TX 75201 T: 972-277-1136See details»
Lantern Pharma Inc. (LTRN)
Lantern Pharma is a clinical stage biotechnology company focused on innovating the cancer drug development process by using advanced genomics, machine learning, and artificial intelligence ("A.I."). Our A.I. platform, known as …See details»
Our Team - Lantern Pharma Inc.
Lantern Pharma prides itself on attracting experts dedicated to the advancement of drug development and biotech pharmaceuticals. Our team has ample experience in all aspects of the life science industry, from high-level project …See details»
Lantern Pharma - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 972-277-1136 Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with …See details»
Lantern Pharma CEO and Key Executive Team | Craft.co
Lantern Pharma's Chief Executive Officer, President and Director is Panna Sharma. Other executives include David R. Margrave, Chief Financial Officer and Secretary; Peter Nara, Co …See details»
Lantern Pharma Inc. (LTRN) Company Profile & Overview - Stock …
1920 McKinney Avenue, 7th Floor Dallas, Texas 75201 United StatesSee details»
Lantern Pharma - Craft
Lantern Pharma is a biotechnology company developing precision cancer drugs. It offers therapies using genomic data, machine learning, and computational biology modeling to …See details»
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives ...
4 days ago You may access our Annual Report on Form 10-K for the year ended December 31, 2023 under the investor SEC filings tab of our website at www.lanternpharma.com or on the …See details»
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 …
DALLAS, March 04, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced a series of important milestones related to the development, size ...See details»
Culture - Lantern Pharma Inc.
Lantern Pharma is dedicated to fostering a workplace environment that keeps our employees inspired and provides them with the vision, resources and support they need to succeed.See details»
Lantern Pharma - Company info. interviews, news - BiopharmaTrend
AI Breaches the Barrier Towards Better CNS Drug Discovery Dec. 28, 2023 The sphere of oncology continues to grapple with the complex nature of brain and central nervous system …See details»
FDA Grants Lantern Pharma Orphan Drug Designation for Drug …
Aug 11, 2021 [email protected] 212-671-1021. Public Relations Nicholas Koulermos, Vice President – 5W Public Relations [email protected] 646-843-1812.See details»
Lantern Pharma Reports Third Quarter 2024 Financial Results and ...
Nov 7, 2024 Related presentation materials will be accessible at: https://ir.lanternpharma.com; A replay of the 3 rd quarter 2024 earnings call and webinar will be available at: …See details»
Press Releases - Lantern Pharma Inc.
Mar 15, 2024 LP-284 is in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ®, as a potential therapy for relapsed or refractory non-Hodgkin’s …See details»
Lantern Pharma and Actuate Therapeutics Announce Research
Feb 23, 2021 Marek Ciszewski, J.D. Director, Investor Relations 628-777-3167 [email protected] About Actuate Therapeutics Actuate Therapeutics, Inc. is a clinical …See details»
Lantern Pharma’s Investigational Drug-Candidate, LP-184
Oct 15, 2024 Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA Fast Track Designation is designed to expedite …See details»
Press Releases - ir.lanternpharma.com
Oct 15, 2024 Fast Track Designation is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need. Fast Track Designation for LP-184 …See details»
Lantern Pharma Reports Second Quarter 2024 Financial Results …
Aug 8, 2024 Related presentation materials will be accessible at: https://ir.lanternpharma.com; A replay of the 2nd quarter 2024 earnings call and webinar will be available at: …See details»